PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-2307
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma ; day:24 ; month:1 ; year:2020 ; pages:1-9
Virchows Archiv ; (24.1.2020), 1-9
- Urheber
-
Martin de la Fuente, Laura
Westbom-Fremer, Sofia
Arildsen, Nicolai Skovbjerg
Hartman, Linda
Malander, Susanne
Kannisto, Päivi
Måsbäck, Anna
Hedenfalk, Ingrid
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-020-02751-6
- URN
-
urn:nbn:de:101:1-2020041901222910397217
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martin de la Fuente, Laura
- Westbom-Fremer, Sofia
- Arildsen, Nicolai Skovbjerg
- Hartman, Linda
- Malander, Susanne
- Kannisto, Päivi
- Måsbäck, Anna
- Hedenfalk, Ingrid
- SpringerLink (Online service)
Ähnliche Objekte (12)
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer